| Autor: |
Papageorgiou, S.G. Kontos, C.K. Kotsianidis, I. Vasilatou, D. Symeonidis, A. Galanopoulos, A. Bouchla, A. Hatzimichael, E. Repousis, P. Zikos, P. Viniou, N.-A. Poulakidas, E. Vassilakopoulos, T.P. Diamantopoulos, P. Diamantopoulos, M.A. Mparmparousi, D. Bouronikou, E. Papadaki, H. Panayiotidis, P. Pappa, V. |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Popis: |
The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of patients achieving stable disease (SD) is unclear. This retrospective study of the Hellenic MDS Study Group included 353 intermediate-2 or high IPSS risk patients treated with 5-AZA. Forty-four out of 86 (51.6%) patients achieving SD and continuing treatment with 5-AZA showed a lower risk of transformation of MDS to acute myeloid leukemia (AML) and increased overall survival (OS), compared to SD patients who discontinued the treatment (estimated median AML-free survival = 38 months, 95% CI = 10.7-65.3 vs 15 months, 95% CI = 10.4-19.6, P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
